No Data
Leerink Partners Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Express News | Cantor Fitzgerald Reiterates Overweight on Tourmaline Bio, Maintains $25 Price Target
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Strategic Developments in Tourmaline Bio's Cardiovascular Programs Drive Buy Rating
Tourmaline Bio Unveils Clinical Progress and New Indication
Trytosaveabit : Larry Fink is a terrible awful person! Sad part it’s hard to trade any ticker that he don’t have a part of! He has been on a buying spree! I’ve seen at least 25 in last 24 hours! Prolly more that he has been buying!